May 29, 2008
Pfizer named Amy Schulman as SVP and general counsel, effective June 23. In her new role, Schulman will be responsible for leading Pfizer's legal division. Schulman joins Pfizer from DLA Piper, where she was a partner and co-leader of the firm's mass tort/class action practice. In that capacity, Schulman handled some of the most complicated legal, scientific and regulatory issues facing the world's most respected companies, including Pfizer. While at DLA Piper, she served as lead national counsel in the multi-district litigation involving Bextra and Celebrex. Schulman joined DLA Piper in 1997 and served on the firm's global board and US executive and policy committees. She also spearheaded a number of the firm's strategic initiatives, most notably in the areas of client service, diversity and inclusiveness, and mentoring.
Schering-Plough has appointed Janet Barth VP, investor relations. In this role, Barth will be responsible for developing, implementing and continually improving a comprehensive global investor relations program for Schering-Plough. She will lead the formulation and execution of external and internal investor communications plans to support Schering-Plough's business objectives. She also will partner with the company's senior management team on matters pertaining to the investment community and individual shareholders. Barth most recently served as senior vice president, investor relations and corporate communications, for Adams Respiratory Therapeutics. In that role, she established, developed and directed comprehensive investor relations and corporate communications programs for the company prior to its acquisition by Reckitt Benckiser in January 2008.
InVentiv Health has announced the appointment of Blane Walter as its CEO. Walter assumes his new role effective June 11, following the company's annual shareholder meeting. Walter, currently president of inVentiv Health, joined the company in conjunction with inVentiv's acquisition of inChord Communications in 2005. As chairman and CEO of inChord, Walter built the agency from a 35 people to a staff of over 1,000.
GSW Worldwide, an inVentiv Health company, announced promotions at its Newtown, PA office. David Payne, formerly product designer, is now associate brand designer. Payne joined GSW Worldwide in September 2007 and previously served as graphic designer for The News Journal in Wilmington, DE. Christopher Redding, formerly editor, is now brand voice writer. Redding has been with GSW Worldwide since August 2006 and previously worked for PharmaWrite, a medical communications company. Paul Smith, formerly senior art director, is now associate creative director. Smith joined GSW Worldwide in 2006 and has more than 10 years of experience in entertainment advertising and promotion. Laura Sneade, formerly interactive planner, is now account director. Sneade has been with GSW Worldwide for nine months and previously served as an account director for imc2.
Vox Medica named George Glatcz president. Glatcz joins from Omnicom's ProEd Communications, where he was president, and has worked for inChord Communications, Monsanto/Searle, DuPont/Merck and Boehringer Mannheim Therapeutics.
Slack Inc. announced the appointment of Frederick Short as sales director of its specialty medicine group. In this position, Short will spearhead sales efforts for Cardiology Today's next generation of medical news, slated to launch this July. He will also oversee sales functions for Infectious Disease News and Diabetes Vital, and be involved with Endocrine Today. Prior to joining Slack, Short served as national account manager at Lippincott Williams & Wilkins/Wolters Kluwer. He worked in a variety of therapeutic areas including plastic surgery, general surgery, pathology, ophthalmology and neurology.
Lippincott Williams & Wilkins has announced the appointment of Bob Williams as national accounts manager for Neurology, Neurology Now and AAN News, published in partnership by the American Academy of Neurology and Lippincott Williams & Wilkins a part of Wolters Kluwer Health.